Visiongain Publishes Vaccine Adjuvants Market Report 2021-2031

Visiongain has published a new report on Vaccine Adjuvants Market Report 2021-2031: Forecasts by Type (Pathogen, Adjuvant Emulsion, Particulate, Combination, Others), by Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others), by Disease Type (Infectious Diseases, Cancer, Others), by End-user (Pediatric, Adults, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Vaccine Adjuvants Companies AND COVID-19 Recovery Scenarios.

The global vaccine adjuvants market is segmented on the basis of region into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to Visiongain analysis, global Vaccine Adjuvants market is estimated to be valued at US$ xx million in 2020. The market is expected to witness a CAGR of xx% from 2021 to 2026 and is expected to reach US$ xx million in 2026 from its previous value of US$ xx million in 2021. Visiongain further anticipates that the global market will reach US$ xx million in 2031 while growing at a CAGR of xx% from 2021 to 2031.

Which Factors are Fuelling Vaccine Adjuvants Industry Growth?
• Growing Investment in Vaccine Development to Fuel Vaccine Adjuvants Market Growth
• Rising R&D Activities by Government and Vaccine Manufacturers
• Growing Government Focus on Immunization Across Emerging Economies to Boost Vaccine Adjuvants Market Growth
• Unmet Vaccine Needs for Certain Diseases

What are the Opportunities for Vaccine Adjuvants Vendors?
• Adjuvants Can Enhance Immune Response
• Vaccine Adjuvants Can Reduce Amount of Vaccine Protein Required Per Dose
• Combination Adjuvants to Offer Lucrative Growth Opportunities for Market Players

Which Factors are Restraining Vaccine Adjuvants Industry Growth?
• Lack of Healthcare Infrastructure Across LMIC (Low and Middle Income) Economies
• Stringent Regulatory Scenarios
• High Cost of Adjuvant Based Research

Opportunity For Innovation Within The Vaccine Adjuvants Market Remains Strong
The opportunity for innovation within the vaccine adjuvants market remains strong. As time progresses, the technology used in the manufacturing and development of vaccines is improved. This will lead to improvements in the manufacturing processes of vaccines that could save costs. Similarly, it allows for innovative vaccine platforms to be researched. This could lead to better vaccines that give a stronger efficacy, or new targets for vaccines could be found. This will all contribute to developing the vaccine adjuvants market.

Indian Vaccine Adjuvants Market to Witness Highest Growth Rate
India is another extremely promising market in the developing world. India is the second largest populous nation in the world with approximately 1.3 billion people in 2020. The Indian vaccine adjuvants market holds great potential due to its sheer population and extremely high birth rates that feeds the vaccine adjuvants demand. However, due to structural and economic barriers, a large proportion of the society is unable to access the vaccines. An estimated 2.5 million lives are lost each year in India due to diseases that are apparently avoidable through vaccines. The low vaccine coverage rates are due to the low per capita vaccine expenditure reported, which in turn results in an unequal market with low access to immunization. According to Visiongain analysis, continuous improvement in healthcare facilities coupled with rising R&D activities by government and major companies are anticipated to fuel the regional vaccine adjuvants market growth.

Competitive Landscape
According to Visiongain analysis, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations, and launching new products to strengthen their position in the global vaccine adjuvants market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the vaccine adjuvants market. Some of the companies profiled in the report include GSK, CSL, Agenus, Adjuvance, Novavax, SPI Pharma, Invivogen, Avanti Polar Lipids, Seppic, Croda, MVP Laboratories, OZ Biosciences, and Dynavax.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.